Elucidation of the mechanism of action for establishing novel strategies of plasmapheresis
| Project/Area Number |
22791086
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kyorin University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 水疱症 / 重症薬疹 / 血漿交換 / サイトカイン / 血漿交換療法 |
|---|
| Research Abstract |
Plasmapheresis (PP) is one of the most effective option for treatment of severe drug eruption and autoimmune blistering disorders. The mechanism of action of PE in these diseases as in other autoantibody-mediated disease remains unknown. In this study, we asked whether alterations of serum cytokine levels and regulatory T cells (Treg) after PE or corticosteroid pulse therapy could be the mechanism of why PE is a much more effective option for treatment of severe drug eruptions and recalcitrant autoimmune diseases than other options. In autoimmune blistering disorders, double-filtration plasmapheresis (DFPP) has been predominantly used, while serum exchange (PE) has been more frequently used for severe drug eruptions than DFPP. We found that high levels of serum IL-10 after PP was associated with its remarkable efficacy in both disease conditions and that serum IL-10 levels may be a more valuable biomarker to identify patients likely to respond to PP in autoimmune blistering disorders than in severe drug eruptions.
|
Report
(3 results)
Research Products
(26 results)
